Diamyd Medical elected to present Diamyd® meta-analysis results at the EASD diabetes conference

A scientific abstract detailing the latest findings from a meta-analysis based on data from more than 600 individuals with type 1 diabetes that have participated in clinical trials with the diabetes vaccine Diamyd[®] (GAD-alum) has been elected to be presented orally  the 57th EASD Annual Meeting (European Association for the Study of Diabetes).The abstract which summarizes the results from the meta-analysis is titled “The influence of HLA haplotype, number of injections and administration route on the effect of GAD-specific immunotherapy in type 1 diabetes" and will be presented live by